Summary: Introduction of the new glucose lowering drugs which improve glycemic control in a glucose ‒ dependent manner and are not likely to cause hypoglycemia is one of the greatest achievements of the modern diabetology. Recently, it has been proven in several large clinical trials that, beyond the anti-hyperglycemic effect, these agents significantly reduced cardiovascular risk and prevented the development and progression of albuminuria and lowered the decline in estimated glomerular filtration rate. Interestingly, some representatives of SGLT-2 in-hibitors and GLP-1 RAs are already approved for use in patients with CHD and HF and in renally impaired patients. There is no doubts that the higher use of these agents will create a real chance to reduce the risk of serious diabetes complications. The objective of this article is to provide family doctors an overview of the currently available data regarding the potential role of these novel agents in the management of patients with T2DM and coexisting cardiovascular and renal diseases.